Individualized leukemia cell-population profiles in common B-cell acute lymphoblastic leukemia patients. 2013

Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Immunophenotype is critical for diagnosing common B-cell acute lymphoblastic leukemia (common ALL) and detecting minimal residual disease. We developed a protocol to explore the immunophenotypic profiles of common ALL based on the expression levels of the antigens associated with B lymphoid development, including IL-7Rα (CD127), cytoplasmic CD79a (cCD79a), CD19, VpreB (CD179a), and sIgM, which are successive and essential for progression of B cells along their developmental pathway. Analysis of the immunophenotypes of 48 common ALL cases showed that the immunophenotypic patterns were highly heterogeneous, with the leukemic cell population differing from case to case. Through the comprehensive analysis of immunophenotypic patterns, the profiles of patient-specific composite leukemia cell populations could provide detailed information helpful for the diagnosis, therapeutic monitoring, and individualized therapies for common ALL.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D051925 CD79 Antigens Components of the B-cell antigen receptor that function in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. They are expressed almost exclusively by B-LYMPHOCYTES and are markers for B-cell NEOPLASMS. Antigens, CD79,Antigens, CD79a,Antigens, CD79b,CD79a Antigens,CD79b Antigens,B-Cell Antigen Receptor Complex Associated Protein Beta-Chain,CD79 Antigen,CD79a Antigen,CD79b Antigen,IgM-Alpha Component,Igbeta Antigen,Immunoglobulin-Associated Alpha Protein,Immunoglobulin-Associated Beta Protein,Antigen, CD79,Antigen, CD79a,Antigen, CD79b,Antigen, Igbeta,B Cell Antigen Receptor Complex Associated Protein Beta Chain,IgM Alpha Component,Immunoglobulin Associated Alpha Protein,Immunoglobulin Associated Beta Protein
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma
D054444 Immunoglobulin Light Chains, Surrogate An immunolglobulin light chain-like protein composed of an IMMUNOGLOBULIN VARIABLE REGION-like peptide (such as light chain like lambda5 peptide) and an IMMUNOGLOBULIN CONSTANT REGION-like peptide (such as Vpreb1 peptide). Surrogate light chains associate with MU IMMUNOGLOBULIN HEAVY CHAINS in place of a conventional immunoglobulin light chains to form pre-B cell receptors. Surrogate Immunoglobulin Light Chains,Surrogate Light Chains,Immunoglobulin Light Chain-Like lambda5 Peptide,Pseudo Immunoglobulin Light Chain,Surrogate Immunoglobulin kappa Light Chain,Surrogate L Chain Protein,Surrogate Light Chain,Surrogate kappa Light Chain,Surrogate lambda Light Chain,VpreB-lambda 5 SL Chain,VpreB-lambda5 Surrogate Light Chain,lambda5 Peptide, Immunoglobulin Light Chain-Like,psi lambda Light Chain,psiL Chain, Immunoglobulin,Immunoglobulin Light Chain Like lambda5 Peptide,Immunoglobulin psiL Chain,Light Chain, Surrogate,Light Chains, Surrogate,VpreB lambda 5 SL Chain,VpreB lambda5 Surrogate Light Chain,lambda5 Peptide, Immunoglobulin Light Chain Like

Related Publications

Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
October 2023, Journal of pediatric hematology/oncology,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
December 2022, International journal of laboratory hematology,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
August 1989, Acta pathologica japonica,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
May 2024, Journal of pediatric hematology/oncology,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
August 2018, Ophthalmology. Retina,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
January 2022, BMC pediatrics,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
November 2005, Personalized medicine,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
February 1995, International journal of hematology,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
March 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Jian-Hua Yu, and Jing-Tao Dong, and Yong-Qian Jia, and Neng-Gang Jiang, and Ting-Ting Zeng, and Hong Xu, and Xian-Ming Mo, and Wen-Tong Meng
January 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society,
Copied contents to your clipboard!